Search PubMed⌕ Search

Biomedical subjects

R Ceska

Publications and source records attributed to R Ceska.

88 records · Page 5Linked to original sources
PubMed1992

[Combined therapy of hyperlipoproteinemia. Colestipol and gemfibrozil in the treatment of heterozygous familial hypercholesterolemia].

Combined concurrent treatment with two or more hypolipidaemic agents is a modern trend in the pharmacotherapy of hyperlipoproteinaemias. Aggressive treatment of hyperlipoproteinaemias can lead not only to the arrest of progression but also to regression of the atherosclerotic process. The authors submit experience assembled with the treatment of 14 heterozygotes with familial hypercholesterolaemia by a combination of colestipol (Colestid Upjohn, Belgium) with gemfibrosil (Loped Parke-Davis, USA), 15 g and 1200 mg resp. per day. One month of administration of this combination of hypolipidaemic agents led to a drop of total cholesterol by 21% and of LDL-cholesterol by 30%. At the same time the authors recorded a marked and statistically significant increase of HDL-cholesterol by 23%. Favourable changes were observed also as regards apolipoprotein concentrations. The apolipoprotein A-1 level increased by 32%, while the level of the atherogenic apolipoprotein B declined by 30%. The triglyceride level declined also. It did not prove possible even by combined treatment to reduce the level of apolipoprotein(a). Combined treatment with colestipol and gemfibrosil was well tolerated by the patients and in none of the patients treatment had to be discontinued because of undesirable side-effects.

Adult↗
PubMed1992

[Colestipol in the treatment of heterozygous familial hypercholesterolemia].

In the specialized clinic for disorders of the lipid metabolism 27 patients, 8 men and 19 women, heterozygotes with familial hypercholesterolaemia were treated for 8 weeks with Colestid (colestipol bags a 5 g, Upjohn, Belgium). The administered dose was 15 g colestipol per day. After colestipol treatment the authors recorded a statistically significant decline of total cholesterol by 18% and of LDL-cholesterol by as much as 27%. The apolipoprotein B concentration declined during treatment by 9% and concurrently there was a favourable rise of apolipoprotein A-1 by 20%. The authors recorded also a slight rise of the HDL-cholesterol concentration which, however, was not statistically significant. The serum triglyceride level increased slightly after colestipol treatment. It did not prove possible to influence the lipoprotein(a) level by colestipol administration. As compared with other hypolipidaemic agents from the group of ion exchange resins, the patients tolerated Colestid surprisingly well. Only one female patient discontinued treatment because of dyspeptic complaints, severe constipation.

Adolescent↗
PubMed1991

Influence of testosterone isobutyrate on serum lipoproteins during replacement therapy of hypogonadal men.

Replacement therapy of hypogonadal men with testosterone isobutyrate, 100 mg by the i.m. route every two weeks, does not lead to a permanent significant change of the lipoprotein spectrum and to an increased risk of stereogenesis. The expected changes in the liver lipase activity and in the lipoprotein spectrum under the influence of the administered androgens are obviously suppressed by the antagonistic action of estrogens formed by conversion from androgens.

Adult↗
PubMed1990

[Bezalip in the treatment of hyperlipoproteinemia].

In a specialized clinic for hyperlipoproteinaemias 15 patients with different types of hyperlipoproteinaemias were treated with bezafibrate (Bezalip R tablets a 200 mg of Boehringer Co.) for a period of four weeks 3 X 1 tablet per day. The administration of Bezalip led to a significant drop of cholesterol (-20%), triglycerides by 40% and LDL-cholesterol (-17%), while the HDL cholesterol level did not change significantly. During treatment a drop of the apolipoprotein B level by 17% occurred, the concentration of apolipoprotein A-I increased by 12%. The drug was well tolerated by the patients, there were no undesirable effects calling for discontinuation of treatment. The results are discussed along with those of other authors who had the opportunity to administer the drug for a prolonged period. The authors mention also briefly the results obtained during treatment of patients with hyperlipoproteinaemias, using other hypolipidaemic drugs.

Adult↗
PubMed1990

[Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].

Within the framework of clinical tests of Etolip (ethophylline clofibrate cps. 125 mg, Pharmaceutical Research Institute Modra) this preparation was administered to 28 patients with different types of hyperlipoproteinaemia in a specialized clinic for disorders of the lipid metabolism. The period of administration was four weeks, the dose 2 cps. twice a day. The effect of this new hypolipidaemic drug was compared with that of Lipathyl. Treatment with Etolip did not affect significantly the cholesterol and triacylglycerol levels, and the concentrations of apolipoprotein B and LDL-cholesterol did not change significantly. All these parameters were affected favourably and significantly by Lipanthyl. Etolip treatment had the favourable effect of elevating the HDL-cholesterol and apolipoprotein A-I level. Etolip was well tolerated by patients and no undesirable side-effects developed. The effects of Etolip as a hypolipidaemic agent are relatively small and are markedly lower than the effect of other registered hypolipidaemics available in the CSSR.

Clofibrate↗
PubMed1989

[Hyperlipoproteinemia and the genetic epidemiology of diabetes mellitus].

Cardiovascular diseases are the most frequent cause of mortality in the sub-population of type II diabetics (cca 600,000 in the CSSR). Type II diabetics very frequently cumulate several very serious risk factors (hyperlipoproteinaemia, arterial hypertension, obesity, hyperuricaemia, smoking) for the manifestation of cardiovascular disease. Concurrent comprehensive treatment of all revealed risk factors is essential for primary prevention. Systematic application of methods of genetic epidemiology in families of affected diabetics helps to detect in time and to treat other affected members of the family. It is at the same time a rational way of primary prevention of cardiovascular disease in the highest risk sub-populations. The authors submit an algorithm of treatment of hyperlipoproteinaemic type II diabetics.

Aged↗
PubMed1989

[Iatropathogenic effect of Mevacor on vitamin D metabolism].

The authors examined 18 heterozygotes with familial hypercholesterolaemia and assessed vitamin D metabolites, parameters of phosphocalcium homeostasis and blood lipids. They investigated the effect of the hypolipidaemic drug lovastatin (Mevacor, Merck, Sharpe Dohme, tbl. 20 mg) on the vitamin D metabolism, using increasing doses of 20 to 80 mg per day. They found normal parameters of phosphocalcium homeostasis, normal plasma concentrations of 1,25-dihydroxyvitamin D but low basal values of 25-dihydroxyvitamin D and elevated plasma levels after three months' treatment with MEVACOR. They confirmed at the same time the hypocholesterolaemic effect of the drug. The authors conclude that heterozygotes with familial hypercholesterolaemia may suffer from vitamin D deficiency and that the positive iatropathogenic effect of MEVACOR, a substance inhibiting the activity of 3 hydroxymethylglutarate coenzyme A reductase can have a supporting effect on the vitamin D homeostasis, in particular in old people with vitamin D deficiency.

Female↗
PubMed1989

[Treatment of familial hypercholesterolemia using Mevacor. Initial experience].

18 patients treated at a specialized consultation centre for disorders of fat metabolism were administered a new-generation hypolipidemic (preparation lovastatin-Mevacor) produced by Merck Sharp and Dohme, which inhibits intracellular synthesis of cholesterol. The study also discusses specific types of heterozygotes with familial hypercholesterolemia representing a homogeneous group of patients with maximum resistance to medication and dietary therapy. Mevacor was administered in increasing doses of 20.40 and 80 mg daily for a three-month period. During therapy cholesterol and apolipoprotein B levels significantly decreased, the former from 10.13 to 7.19 mmol/l, the latter from 1.95 to 1.49 g/l. Protective HDL cholesterol significantly increased from 1.01 to 1.23 mmol/l without the triglyceride level indicating any significant change. The course of therapy did not result in any undesirable effects necessitating drug discontinuation. During the clinical testing the patients' weight remained unchanged.

Adolescent↗
PubMed1989

[Gemfibrozil in the treatment of hyperlipoproteinemia].

Within the framework of clinical tests of the preparation Gevilon (gemfibrosil tablets 450 mg) of Parke-Davis Co. this hypolipidaemic preparation was administered to 28 patients with different types of hyperlipoproteinaemia. One-month administration of gemfibrosil, 900 mg per day, significantly influenced some parameters of the lipid and lipoprotein metabolism. Plasma cholesterol declined by 20%, triglycerides by as much as 60%. On the other hand, the HDL cholesterol level did not change. The concentration of the "risk" apolipoprotein B declined by 11%, that of apolipoprotein A1 which is considered protective from the aspect of ischaemic heart disease increased by 21%. There is a significant decline of lipoprotein Lp(a) which was not described in hypolipidaemic drugs of the clofibrate type. Treatment with Gevilon led also to a marked decline of the serum uric acid level. Gemfibrisol is according to the authors' experience as well as according to the results of other authors an effective hypolipidaemic agent suitable for the majority of patients with hyperlipoproteinaemia. Treatment with gemfibrosil leads to a significant decline of the prevalence of ischaemic heart disease.

Adolescent↗
PubMed1989

[Apolipoprotein B, a risk factor in ischemic heart disease: possibilities of its determination using Czechoslovak-manufactured antisera].

When studying disorders fat metabolism in respect to ischemic heart disease great attention has been recently paid first of all to the protein component of lipoprotein complexes, apolipoproteins. Apolipoproteins seem to be much more sensitive indicators of coronary atherosclerosis risk than so far commonly used "lipid" ones. In the presented study we introduce our experience concerning apolipoprotein B assessment by means of rocket technique using foreign made antisera in comparison with antiserum of the Czechoslovak production made by USOL Prague. Our results are comparable with those of foreign and Czechoslovak authors who assessed apolipoprotein B by technically more demanding methods. When using antisera USOL and Behring the established values of apolipoprotein B are comparable both in patients in whom fat metabolism disorder was not proved and in patients with familial hypercholesterolaemia in whom the values of apolipoprotein B are the highest. Indications of apolipoprotein B investigation and its significance for clinical practice are discussed.

Apolipoproteins B↗
PubMed1988

Blood plasma apolipoproteins A-I and B in different types of hyperlipoproteinaemia: comparative analysis of population groups in Moscow and Prague.

The level of blood plasma apolipoproteins A-I and B was studied in Moscow and Prague residents with different types of hyperlipoproteinaemia (HLP). The analysis proceeded in two directions. On the one hand, lipoprotein (LP) spectra in residents of both cities with the same type of LP disturbance (HLP type IIa, IIb or IV) were compared; in Prague lipid and apolipoprotein content was compared in inhabitants with a normal lipid level and those with HLP types I, III and V. The analysis showed that inhabitants of Prague with types II and IV HLP have a higher concentrations of high density LP cholesterol. At the same time, it was found that the apolipoprotein profile of blood plasma LP in HLP patients was similar to that in patients living elsewhere. The authors regard comparative study of LP system disturbances in residents of different cities and countries differing in their geographical, ethnic and ecological conditions as a promising approach to understanding the mechanisms responsible for the development of HLP.

Adult↗